Osteoporosis International

, Volume 20, Issue 12, pp 1989–1998 | Cite as

Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates

  • F. de Vries
  • A. L. Cooper
  • S. M. Cockle
  • T.-P. van Staa
  • C. Cooper
Original Article



Previous studies have found an association between acid suppressants and fracture risk. We assessed fracture risk in patients taking concomitant acid suppressant and bisphosphonates. Positive associations were observed for any hip and vertebral fracture. The effect size was modest; however, the significance lies in the widespread prescribing of acid suppressants.


Previous studies have found that acid-suppressive medication (ASM) is associated with an increased risk of fracture. Bisphosphonates can cause upper gastrointestinal problems, and patients may be prescribed ASM to minimise these effects.


A retrospective cohort study using the GPRD was conducted in patients aged 40 years and older starting proton pump inhibitors (PPI, N = 234,144), H2 receptor antagonists (H2RA, N = 166,798) or bisphosphonates (N = 67,309). Fracture risk in current versus past use of ASM and concomitant use of bisphosphonate plus ASM versus bisphosphonate alone was compared using time-dependent Cox regression.


In the 6 months before initiating bisphosphonate therapy, 20.1% of patients received a PPI and 7.5% an H2RA. Current PPI use was associated with an increased risk of any (adjusted relative rate (ARR) 1.15, 95% CI 1.10–1.20), hip (ARR 1.22, 95% CI 1.10–1.37), and vertebral fracture (ARR 1.40, 95% CI 1.11–1.78); and concomitant bisphosphonates and PPIs with an increased risk of any (ARR 1.08, 95% CI 1.01–1.16) and hip fracture (ARR 1.24, 95% CI 1.08–1.42).


ASM is associated with an increased risk of fracture when taken alone or in combination with bisphosphonates. Given the frequency of coprescription of ASM and bisphosphonates, this issue requires further investigation.


Bisphosphonate Cohort study Fracture risk H2 receptor antagonists Osteoporosis Proton pump inhibitors 


  1. 1.
    Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin N Am 32:617–629CrossRefGoogle Scholar
  2. 2.
    Bass E, French DD, Bradham DD et al (2007) Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 17(7):514–519CrossRefPubMedGoogle Scholar
  3. 3.
    Leibson CL, Tosteson AN, Gabriel SE et al (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50(10):1644–1650CrossRefPubMedGoogle Scholar
  4. 4.
    Van Staa TP, Dennison EM, Leufkens HGM et al (2001) Epidemiology of fractures in England & Wales. Bone 29(6):517–522CrossRefPubMedGoogle Scholar
  5. 5.
    Nevalainen TH, Hiltunen LA, Jalovaara P (2004) Functional ability after hip fracture among patients home-dwelling at the time of fracture. Cen Eur J Public Health 12(4):211–216Google Scholar
  6. 6.
    Osnes EK, Lofthus CM, Meyer HE et al (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15(7):567–574CrossRefPubMedGoogle Scholar
  7. 7.
    Biswas PN, Wilton LV, Shakir SAW (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507–514CrossRefPubMedGoogle Scholar
  8. 8.
    Barrera BA, Wilton LV, Harris S et al (2005) Prescription-event monitoring study on 13, 164 patients prescribed risedronate in primary care in England. Osteoporos Int 16:1989–1998CrossRefPubMedGoogle Scholar
  9. 9.
    Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57(6):813–816CrossRefPubMedGoogle Scholar
  10. 10.
    Yang YX, Lewis JD, Epstein S et al (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953CrossRefPubMedGoogle Scholar
  11. 11.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79(2):76–83CrossRefPubMedGoogle Scholar
  12. 12.
    Yu E, Shinoff C, Blackwell T, Ensrud K, Hillier T, Bauer C (2006) Use of acid-suppressive medications and risk of bone loss and fracture in postmenopausal women. J Bone Min Res 21(Suppl. 1):S281Google Scholar
  13. 13.
    Van Staa TP, Leufkens HGM, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fracture. J Bone Miner Res 15(6):993–1000CrossRefPubMedGoogle Scholar
  14. 14.
    Van Staa TP, Leufkens HGM, Cooper C (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31(4):508–514CrossRefPubMedGoogle Scholar
  15. 15.
    Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179(4):319–326PubMedGoogle Scholar
  16. 16.
    Grisso JA, Kelsey JL, O’Brien LA et al (1997) Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 145(9):786–793PubMedGoogle Scholar
  17. 17.
    O’Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781CrossRefPubMedGoogle Scholar
  18. 18.
    Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, Russell RR (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14(4):364–368PubMedGoogle Scholar
  19. 19.
    Zaidi M (1990) Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function. Biosci Rep 10(6):547–556CrossRefPubMedGoogle Scholar
  20. 20.
    Mattsson JP, Väänänen K, Wallmark B et al (1991) Omeprazole and bifailomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1065(2):261–268CrossRefPubMedGoogle Scholar
  21. 21.
    AstraZeneca (2008) Losec (omeprazole). Summary of Product Characteristics. AstraZeneca, LondonGoogle Scholar
  22. 22.
    Wyeth (2007) Zoton FasTab (lansoprazole). Summary of Product Characteristics. Wyeth, MadisonGoogle Scholar
  23. 23.
    Penning-van Beest FJ, Goettsch WG, Erkens JA et al (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236–242CrossRefPubMedGoogle Scholar
  24. 24.
    Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921CrossRefPubMedGoogle Scholar
  25. 25.
    Hungin AP, Rubin G, O’Flanagan H (1999) Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49(443):463–464PubMedGoogle Scholar
  26. 26.
    Cramer JA, Gold DT, Silverman SL et al (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18(8):1023–1031CrossRefPubMedGoogle Scholar
  27. 27.
    De Vries F, Bracke M, Leufkens HGM, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoids therapy. Arthritis Rheum 56(1):208–214CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • F. de Vries
    • 1
    • 2
  • A. L. Cooper
    • 3
  • S. M. Cockle
    • 4
  • T.-P. van Staa
    • 1
    • 2
  • C. Cooper
    • 5
    • 6
  1. 1.Utrecht Institute for Pharmaceutical SciencesUniversiteit UtrechtUtrechtThe Netherlands
  2. 2.General Practice Research DatabaseMHRALondonUK
  3. 3.Bridge Medical CentreCrawleyUK
  4. 4.Servier Laboratories Ltd.Wexham, SloughUK
  5. 5.MRC Epidemiology Resource CentreUniversity of SouthamptonSouthamptonUK
  6. 6.Norman Collisson Chair of Musculoskeletal SciencesUniversity of OxfordOxfordUK

Personalised recommendations